Shui Yee Leung

Dr. Shui Yee Leung

School of Pharmacy, Faculty of Medicine, The Chinese University of Hong Kong,Hong Kong, China
orcid

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2015 in Advanced Drug Delivery Reviews
Verified
Journal Article
Closed access
QZQi (Tony) Zhou
Qi (Tony) Zhou
SLShui Yee Leung
Shui Yee Leung
PTPatricia Tang
Patricia Tang
TPTHAIGARAJAN PARUMASIVAM
THAIGARAJAN PARUMASIVAM
ZLZhi Hui Loh
Zhi Hui Loh
HCHak-Kim Chan
Hak-Kim Chan

1 August 2018 in Advanced Drug Delivery Reviews
Verified
Journal Article
Closed access
Rachel Yoon ChangRachel Yoon Chang
Rachel Yoon Chang
MWMartin Wallin
Martin Wallin
YLYu Lin
Yu Lin
SLShui Yee Leung
Shui Yee Leung
HWHui Wang
Hui Wang
HCHak-Kim Chan
Hak-Kim Chan

1 August 2014 in Advanced Drug Delivery Reviews
Verified
Journal Article
Closed access
QZQi (Tony) Zhou
Qi (Tony) Zhou
PTPatricia Tang
Patricia Tang
SLShui Yee Leung
Shui Yee Leung
JCJohn Gar Yan Chan
John Gar Yan Chan
HCHak-Kim Chan
Hak-Kim Chan

3 July 2020 in Frontiers in Pharmacology
Verified
Journal Article
Open access
PDF file
HZHuixi Zou
Huixi Zou
PBParikshit Banerjee
Parikshit Banerjee
SLShui Yee Leung
Shui Yee Leung
XYXiaoyu Yan
Xiaoyu Yan
With the advancement of technology, drug delivery systems and molecules with more complex architecture are developed. As a result, the drug absorption and disposition processes after administration of these drug delivery systems and engineered molecules become exceedingly complex. As the pharmacokinetic and pharmacodynamic (PK-PD) modeling allows for the separation of the drug-, carrier- and pharmacological system-specific parameters, it has been widely used to improve understanding of the in vivo behavior of these complex delivery systems and help their development. In this review, we summarized the basic PK-PD modeling theory in drug delivery and demonstrated how it had been applied to help the development of new delivery systems and modified large molecules. The linkage between PK and PD was highlighted. In particular, we exemplified the application of PK-PD modeling in the development of extended-release formulations, liposomal drugs, modified proteins, and antibody-drug conjugates. Furthermore, the model-based simulation using primary PD models for direct and indirect PD responses was conducted to explain the assertion of hypothetical minimal effective concentration or threshold in the exposure-response relationship of many drugs and its misconception. The limitations and challenges of the mechanism-based PK-PD model were also discussed.

29 February 2016 in Pharmaceutical Research
Verified
Journal Article
Closed access
PDF file
SLShui Yee Leung
Shui Yee Leung
TPTHAIGARAJAN PARUMASIVAM
THAIGARAJAN PARUMASIVAM
FGFiona G. Gao
Fiona G. Gao
NCNicholas B. Carrigy
Nicholas B. Carrigy
RVReinhard Vehring
Reinhard Vehring
HCHak-Kim Chan
Hak-Kim Chan

1 November 2020 in International Journal of Pharmaceutics
Verified
Journal Article
Closed access
WLWing Ching Bianca Lai
Wing Ching Bianca Lai
XCXi Chen
Xi Chen
MHMarco Kai Yuen Ho
Marco Kai Yuen Ho
JXJiang Xia
Jiang Xia
SLShui Yee Leung
Shui Yee Leung